<DOC>
	<DOC>NCT00962065</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study of LX4211 in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Males and females (nonchildbearing potential), aged 1865 years Diagnosis of Type 2 diabetes mellitus for at least 6 months prior to screening Fasting plasma glucose ≤ 240 mg/dL prior to metformin washout Body mass index &lt; 42 kg/m^2 HbA1c value of 7 to 11% Cpeptide ≥ 1.0 ng/mL Ability to provide written informed consent History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, incontinence, or nocturia Use of any blood glucose lowering agent other than metformin Prior exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening Laboratory or electrocardiogram abnormalities deemed significant by the Sponsor or the Investigator Positive test result for glutamic acid decarboxylase (GAD) antibody Surgery within 6 months of screening Exposure to any investigational agent or participation in any investigational trial within 30 days prior to Day 1 Hypersensitivity to an SGLT2 inhibitor History of drug or alcohol abuse within the last 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>